Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Amelubant (BIIL 284) Formulations in Healthy Males
NCT02265666Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2001
- Primary completion
- Nov 2001
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of amelubant in rheumatoid arthritis (RA), cystic fibrosis (CF), asthma and 1 more (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity up to 24 hours and Maximum measured concentration of the analyte in plasma up to 24 hours. Started Oct 2001; status: completed.
02
Drugs
amelubant
03
Conditions
rheumatoid arthritis (RA)cystic fibrosis (CF)asthmapsoriasis
Beyond the preview
Go deeper on NCT02265666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02265666.